Oncology and Hematology

Episodes 17-32 of 485

Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
Advances in Women's Health
Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
- Ann Klopp, M.D., Ph.D.
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Project Oncology®
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Project Oncology®
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Project Oncology®
Targeting CCR4 in CAR-Associated Peripheral T-Cell Lymphoma
Addressing Psychological Distress in Lung Cancer: The Emerging Role of EMDR Therapy
Addressing Psychological Distress in Lung Cancer: The Emerging Role of EMDR Therapy
Project Oncology®
Addressing Psychological Distress in Lung Cancer: The Emerging Role of EMDR Therapy
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
Project Oncology®
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
- Jennifer Caudle, DO
- Patrick McGill, MD
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
Project Oncology®
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
- Jacob Sands, MD
- Joshua K. Sabari, MD
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
CME/CE
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
0.25 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Christophe Le Tourneau, MD, PhD
0.25 credits
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
Project Oncology®
Durable Outcomes in NSCLC: 6-Year Survival Findings from CheckMate 9LA
- Jacob Sands, MD
- Sandip Patel, MD
6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
Project Oncology®
6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
- Jacob Sands, MD
- Millie Das, MD
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Project Oncology®
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
- Charles Turck, PharmD, BCPS, BCCCP
- Evandro Bezerra, MD
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Project Oncology®
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
- Charles Turck, PharmD, BCPS, BCCCP
- Evandro Bezerra, MD
Mutational Complexity in ROS1-Positive mNSCLC: Insights from Real-World Practice
Mutational Complexity in ROS1-Positive mNSCLC: Insights from Real-World Practice
Project Oncology®
Mutational Complexity in ROS1-Positive mNSCLC: Insights from Real-World Practice
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
Project Oncology®
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
- Charles Turck, PharmD, BCPS, BCCCP
- Marwan G. Fakih, MD
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
Project Oncology®
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
- Brian P. McDonough, MD, FAAFP
- Marie Wood, MD
Integrating MCED Testing in Practice: Best Practices for Enhancing Cancer Screening
Integrating MCED Testing in Practice: Best Practices for Enhancing Cancer Screening
Project Oncology®
Integrating MCED Testing in Practice: Best Practices for Enhancing Cancer Screening
- Brian P. McDonough, MD, FAAFP
- Mylynda Massart, MD, PhD